Back to top
more

Poseida Therapeutics (PSTX)

(Delayed Data from NSDQ)

$9.45 USD

9.45
2,108,202

+0.04 (0.43%)

Updated Dec 20, 2024 03:59 PM ET

After-Market: $9.52 +0.07 (0.74%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.35%
2Buy18.11%
3Hold9.74%
4Sell5.34%
5Strong Sell2.80%
S&P50011.41%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

by Zacks Equity Research

Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

by Kinjel Shah

RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B

by Zacks Equity Research

RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know

by Zacks Equity Research

Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Poseida Therapeutics (PSTX) delivered earnings and revenue surprises of 150% and 378.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics (PSTX) delivered earnings and revenue surprises of 25.58% and 88.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice

by Zacks Equity Research

Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -16.67% and 23.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Adaptimmune (ADAP) Down on End of Collaboration With Roche

by Zacks Equity Research

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 25% and 99.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Universal Health Services (UHS) delivered earnings and revenue surprises of 3.64% and 1.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 12.50% and 67.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 19.35% and 16.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 13.56% and 142.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -12.50% and 3.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?